FDA
No application listedNo application naming selank as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDASelank: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is Selank?
Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, built on the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension. Published work includes rodent studies, one resting-state imaging study and one analytical identification. It is supplied here as a research material for laboratory use only.
What are the chemical facts for Selank?
- Name
- Selank
- Also written
- TP-7
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Length
- 7 residues
- Molecular formula
C33H57N11O9(matches the formula computed from the sequence)- Average molecular weight
- 751.9 g/mol
- CAS number
129954-34-3(confirmed in PubChem)- PubChem
- CID 11765600
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of Selank?
- A rat study measured object-recognition memory and BDNF content in brain structures after long-term ethanol exposure.[3]
- A rat study measured behaviour in a 6-OHDA model of parkinsonism after Semax and Selank.[4]
- A resting-state imaging study measured whole-brain functional connectivity in 52 healthy participants for Selank and Semax.[1]
What has published research on Selank looked at?
4 studies are cited for Selank. Each is labelled by design below, and each entry says what the paper measured.
- 2 animal study
- 1 human study
- 1 analytical chemistry
PubMed returns 126 records for the search terms published on the method page (4 of them with a review publication type, 8 with a clinical-trial publication type), checked 5 October 2026. ClinicalTrials.gov lists 2 registered studies whose intervention matches the name (2 interventional), checked 5 October 2026.
- Selank and Semax were identified by analytical methods in seized pharmaceutical preparations; the authors state that, to their knowledge, neither has completed clinical trials.[2]
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of Selank?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names selank as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "selank". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Not namedThe WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for Selank?
[1] Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, et al.. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490:9-11.
Measured whole-brain resting-state functional connectivity in 52 healthy participants for Selank and Semax.
[2] Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal. 2020;12:371-381.
Identification of Selank and Semax in seized pharmaceutical preparations by analytical methods. The authors state that neither has completed clinical trials, to their knowledge.
[3] Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019;167:641-644.
Measured object-recognition memory and BDNF content in brain structures of rats after long-term ethanol exposure.
[4] Slominsky PA, Shadrina MI, Kolomin TA, Stavrovskaya AV, Filatova EV, Andreeva LA, et al.. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Dokl Biol Sci. 2017;474:106-109.
Measured behaviour in a rat model of parkinsonism after Semax and Selank.
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is Selank covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.